F. Arriba

发表

Effect of rhG-CSF on the mobilization of CD38 and HLA-DR subfractions of CD34+ peripheral blood progenitor cells

F. Ortuño, J. Rivera, M. Lozano, 1995, Annals of Hematology.

A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

M. Terol, A. Órfão, A. Oriol, 2013, Leukemia.

after stem cell transplantation Long-term prognostic significance of response in multiple myeloma

J. Besalduch, J. Bladé, J. Lahuerta, 2012 .

A Phase I/II National, Multi-Center, Open-Label Study of Bortezomib Plus Melphalan and Prednisone (V-MP) in Elderly Untreated Multiple Myeloma (MM) Patients.

D. Esseltine, M. Terol, F. Prósper, 2004 .

Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin

J. Corral, V. Vicente, A. Ordóñez, 2008, Laboratory Investigation.

Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

M. Terol, A. Órfão, E. Dı́az-Rodrı́guez, 2012, Leukemia.

Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma

H. Johnsen, M. Terol, M. Pérez‐Andrés, 2011, Leukemia.

Autoaggression syndrome resembling acute graft-versus-host disease grade IV after autologous peripheral blood stem cell transplantation for breast cancer

F. Ortuño, J. Corral, F. Ayala, 1999, Bone Marrow Transplantation.

Bone marrow steady-state CD34+/CD71− cell content is a predictive value of rG-CSF-mobilized CD34+ cells

F. Ortuño, M. Lozano, V. Vicente, 1998, Bone Marrow Transplantation.

Thalidomide/Dexamethasone (TD) Vs. Bortezomib(Velcade®)/Thalidomide/Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcade® As Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Younger Patients with Multiple Myeloma (MM): First Results of a Prospective Phase III PETHEMA/Gem Trial

M. Terol, J. Miguel, A. Oriol, 2008 .

Response to imatinib mesylate in patients with hypereosinophilic syndrome

J. Hernández-Rivas, N. Gutiérrez, J. Rodríguez, 2012, International Journal of Hematology.

The Presence of MDS-like Phenotypic Abnormalities (MDS-PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients with MDS/AML-Related Somatic Mutations and Inferior Survival

F. Prósper, Marcos González, J. Miguel, 2016 .

Thalidomide / Dexamethasone (TD) Vs. Bortezomib (Velcade)â/Thalidomide / Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcadeâ as Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Phase III PETHEMA/GEM Trial.

M. Terol, J. Miguel, A. Oriol, 2009 .

Multicenter, Randomized, Open-Label, Phase III Trial of Lenalidomide-Dexamethasone (Len/dex) Vs Therapeutic Abstention in Smoldering Multiple Myeloma at High Risk of Progression to Symptomatic MM: Results of the First Interim Analysis.

F. Prósper, A. Oriol, J. Bargay, 2009 .

with multiple myeloma: results of a multicenter phase 1/2 study Bortezomib plus melphalan and prednisone in elderly untreated patients

D. Esseltine, A. Oriol, J. Bargay, 2011 .

A Prospective, Multicenter, Randomized, Trial of Bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide/Prednisone (VTP) as Induction Therapy Followed by Maintenance Treatment with Bortezomib/Thalidomide (VT) Versus Bortezomib/Prednisone (VP) in Elderly Untreated Patients with Multiple

M. Terol, A. Oriol, N. Gutiérrez, 2009 .

Smoldering Multiple Myeloma (SMM) at High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) as Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment

F. Prósper, J. Miguel, A. Oriol, 2010 .

A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib

J. Miguel, A. Oriol, J. Bladé, 2010 .

ADMINISTRATION OF rHuG–CSF TO YOUNG DONORS

A. Verdeguer, M. Sanz, S. Brunet, 2002 .

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

N. Puig, M. Calasanz, A. Oriol, 2018, Blood.

Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF

F. Ortuño, F. Ayala, M. Lozano, 2000, Bone Marrow Transplantation.

Persistent cytotoxic T lymphocyte expansions after allogeneic haematopoietic stem cell transplantation: kinetics, clinical impact and absence of STAT3 mutations

F. Ortuño, A. Hurtado, T. Chen-Liang, 2016, British journal of haematology.

Hyperdiploidy as a rare event that accompanies poor prognosis markers in CLL

J. Hernández-Rivas, J. Galende, C. Robledo, 2017, European journal of haematology.

Long-term outcome of allogeneic PBSC transplantation in pediatric patients with hematological malignancies: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON) and the Spanish Group for Allogeneic Peripheral Blood Transplantation (GETH)

A. Verdeguer, S. Brunet, J. Díez, 2005, Bone Marrow Transplantation.

Administration of recombinant human granulocyte colony-stimulating factor to normal donors: results of the Spanish National Donor Registry

C. Solano, A. Verdeguer, S. Brunet, 1999, Bone Marrow Transplantation.

Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial

A. Oriol, J. Bladé, J. Lahuerta, 2017, Leukemia.

Risk assessment and outcome of chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation in pediatric patients

A. Verdeguer, S. Brunet, J. Díez, 2004, Bone Marrow Transplantation.

Immune recovery after autologous or rhG‐CSF primed PBSC transplantation

F. Ortuño, M. Lozano, M. Lozano, 1996, European journal of haematology.

A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

M. Terol, A. Órfão, A. Oriol, 2013, Leukemia.

expert committee of the Spanish Myeloma Group from the PETHEMA group

F. Prósper, J. S. San Miguel, J. Bargay, 2016 .

Safety and ef fi cacy of pomalidomide plus low-dose dexamethasone in STRATUS ( MM-010 ) : a phase 3 b study in refractory multiple myeloma

H. Goldschmidt, G. Morgan, M. Dimopoulos, 2016 .

Effect of chemotherapy with alkylating agents on the yield of CD 34 + cells in patients with multiple myeloma

J. Besalduch, J. Ribera, J. Bladé, 2006 .

Maryam ArefiJuan L. GarciaM. Montserrat BrizFelipe de ArribaJuan N. Rodriguez • Guillermo Martin-NunezJoaquin MartinezJavier LopezJulio G. Suarez • M. JoseMorenoM. Angeles MerinoNorma C. GutierrezJesus Maria Hernandez-Rivas

M. Arefi, F. Arriba, M. Moreno, 2012 .

Aplastic Anaemia Induced by Ticlopidine after Placement of Coronary Artery Stents

J. Moraleda, F. Arriba, F. Ferrer, 1998 .

Bortezomib (Velcade)-Melphalan-Prednisone (VMP) Versus Velcade- Thalidomide-Prednisone (VTP) in Elderly Untreated Multiple Myeloma Patients: Which Is the Best Partner for Velcade: An Alkylating or An Immunomodulator Agent?

M. Terol, J. Miguel, A. Oriol, 2008 .

Maintenance Therapy After Stem-Cell Transplantation for Multiple Myeloma with Bortezomib/Thalidomide Vs. Thalidomide Vs. alfa2b-Interferon: Final Results of a Phase III Pethema/GEM Randomized Trial

J. Miguel, A. Oriol, J. Bladé, 2012 .

Analysis of Immunophenotypic Response (IR) by Multiparameter Flow Cytometry In 516 Myeloma Patients Included In Three Consecutive Spanish Trials

M. Terol, J. Miguel, A. Oriol, 2010 .

VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study

A. Oriol, N. Gutiérrez, J. San-Miguel, 2018, Blood.

Carpal tunnel syndrome and vitamin B6

T. López-Alburquerque, F. Arriba, F. Mateos, 1989, Klinische Wochenschrift.

Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment

N. Puig, M. Calasanz, A. Oriol, 2019, Blood.

Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg/m2 and Dexamethasone Plus/Minus Cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex)

A. Oriol, E. Ocio, J. San-Miguel, 2020 .

Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.

F. Prósper, J. Miguel, A. Oriol, 2016 .

Prospective Randomized Study Comparing the Efficacy of Bioequivalent Doses of glycosylated and nonglycosylated rG‐CSF for Mobilizing Peripheral Blood Progenitor Cells

F. Ortuño, F. de Arriba, M. Lozano, 1997, British journal of haematology.

Genetic variants of the extra‐large stimulatory Gs protein alpha‐subunit and risk of thrombotic and haemorrhagic disorders

J. Corral, V. Vicente, J. Guerrero, 2004, British journal of haematology.

A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control This article has been corrected since Advance Online Publication and a corrigendum is also printed in this issue

A. Oriol, L. Corchete, E. Ocio, 2013 .

Long Term Follow-up on the Tretament of High Risk Smoldering Myeloma with Lenalidomide Plus Low Dose Dex (Rd) (phase III spanish trial): Persistent Benefit in Overall Survival

F. Prósper, J. Miguel, A. Oriol, 2014 .